MBIO on Nasdaq

MUSTANG BIO, INC.

MUSTANG BIO, INC. is an American pharmaceutical preparations company based in Worcester.2 Its shares trade on Nasdaq under the symbol MBIO.2

Price unavailable

Last updated Oct 20, 2026.

Overview

-$1.9MNet income, fiscal 20253

Compare with another stock.

  • TickerMBIO on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersNew York, United States2
  • Incorporated inDE4
  • Business address95 Sawyer Rd, Suite 110, Waltham, Ma 024534
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation2
  • LEI5493004W0VC1DPECQ7792
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O INCORPORATING SERVICES, LTD., 19901 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 57094162

See how the biggest companies compare on our leaderboards

Mustang Bio, Inc. (“Mustang,” “we,” “us,” “our” or the “Company”) is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs into potential cures for difficult-to-treat cancers. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-20.2%Return on equity3

Financial statements

Operating income678910113-$2.4M in 2025−92% since 2018
-$80.0M-$60.0M-$40.0M-$20.0M02018: -$31.2M-$31.2M20182019: -$45.9M-$45.9M2019+47%2020: -$56.8M-$56.8M2020+24%2021: -$66.7M-$66.7M2021+17%2022: -$76.2M-$76.2M2022+14%2023: -$49.3M-$49.3M2023−35%2024: -$16.2M-$16.2M2024−67%2025: -$2.4M-$2.4M2025−85%
Net income678910113-$1.9M in 2025−94% since 2018
-$80.0M-$60.0M-$40.0M-$20.0M02018: -$30.7M-$30.7M20182019: -$46.4M-$46.4M2019+51%2020: -$60.0M-$60.0M2020+29%2021: -$66.4M-$66.4M2021+11%2022: -$77.5M-$77.5M2022+17%2023: -$51.6M-$51.6M2023−33%2024: -$15.8M-$15.8M2024−69%2025: -$1.9M-$1.9M2025−88%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Research and development-$1.5M$8.4M
Asset impairment$0$3.7M
General and administrative$3.9M$4.1M
Total operating expenses$2.4M$16.2M
Loss from operations-$2.4M-$16.2M
Other income$0$314.0K
Interest income, net$511.0K$179.0K
Total other income$511.0K$493.0K
Net Loss-$1.9M-$15.8M
Net loss per Class A common and common shares outstanding, basic-$0.39-$38.57
Net loss per Class A common and common shares outstanding, diluted-$0.39-$38.57
Weighted average number of Class A common and common shares outstanding, basic4.9M shares609.7K shares
Weighted average number of Class A common and common shares outstanding, diluted4.9M shares609.7K shares

Compare MUSTANG BIO, INC. with another company

Corporate structure

MUSTANG BIO, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of MUSTANG BIO, INC.

  • INTRACOASTAL CAPITAL, LLC Filed SCHEDULE 13G/A on MUSTANG BIO, INC., latest Aug 12, 2025 (3 filings since Feb 11, 2025)
  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on MUSTANG BIO, INC., latest May 15, 2025 (4 filings since Feb 14, 2024)
  • MUSTANG BIO, INC. New York, New York, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What MUSTANG BIO, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation$5.1M11 Dec 31, 2024$4.5M11 Dec 31, 2023+15.0%
Property and equipment, net$03 Dec 31, 2025$371.0K3 Dec 31, 2024−100.0%
Operating-lease assets (leased space)$03 Dec 31, 2025$81.0K3 Dec 31, 2024−100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$17.3M3 Dec 31, 2025$6.8M3 Dec 31, 2024+152.5%

Properties, in its own words

Our corporate and executive office is located at 95 Sawyer Road, Waltham, MA 02453.

Item 2 of the 10-K filed Mar 19, 2026.5

Leadership

Who has led MUSTANG BIO, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Manuel Litchman Md.2017–now

Chair

  1. Michael S. Weiss2017

President

  1. Manuel Litchman Md.2017–now

Chief financial officer

  1. David J. Horin2017
  2. Eliot M. Lurier2022
  3. James B. Murphy2024
  4. Manuel Litchman Md.2025–now
20202025
Board members and other officers (8)

Timeline

  1. Oct 15, 20268-K Other events29
  2. Apr 17, 20268-K Listing notice or transfer30
  3. Dec 23, 20258-K Shareholder vote; Other events31
  4. Jul 9, 20258-K Other events32
  5. Mar 5, 20258-K Other events33
  6. Feb 27, 20258-K Completed an acquisition or sale; Other events34
  7. Feb 21, 20258-K Shareholder vote35
  8. Feb 13, 20258-K Entered a material agreement; Ended a material agreement36
  9. Feb 11, 20258-K Entered a material agreement; Other events37
  10. Jan 17, 20258-K Change to shareholders' rights; Bylaws or fiscal year changed; Other events38
  11. Jan 10, 20258-K Shareholder vote39
  12. Jan 2, 20258-K Shareholder vote40
  13. Jun 30, 2017New chief executive Manuel Litchman Md. becomes CEO16
  14. Mar 13, 2015Founded MUSTANG BIO, INC. is founded2

Calendar

Coming up

  1. Nov 6, 2026Reports results for the quarter ending Sep/202641

When it reported results

  1. Apr 29, 2024Reported quarterly or annual results42
  2. Mar 11, 2024Reported quarterly or annual results43
  3. Nov 14, 2023Reported quarterly or annual results44
  4. Aug 14, 2023Reported quarterly or annual results45
  5. May 12, 2023Reported quarterly or annual results46
  6. Mar 29, 2023Reported quarterly or annual results47
  7. Nov 14, 2022Reported quarterly or annual results48
  8. Aug 11, 2022Reported quarterly or annual results49

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

202 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 63 major events, 35 insider forms, 15 large holders, 2 private raises, 67 other. The latest 20:

  1. Oct 15, 20268-K EDGAR
  2. Aug 5, 202610-Q EDGAR
  3. May 5, 202610-Q EDGAR
  4. Apr 27, 20264 OWNERSHIP DOCUMENT EDGAR
  5. Apr 17, 20268-K EDGAR
  6. Mar 19, 202610-K EDGAR
  7. Jan 5, 20264 EDGAR
  8. Jan 5, 2026SCHEDULE 13D/A EDGAR
  9. Dec 30, 20254 OWNERSHIP DOCUMENT EDGAR
  10. Dec 30, 20254 OWNERSHIP DOCUMENT EDGAR
  11. Dec 30, 20254 OWNERSHIP DOCUMENT EDGAR
  12. Dec 23, 20258-K EDGAR
  13. Dec 3, 2025DEF 14A EDGAR
  14. Nov 7, 202510-Q EDGAR
  15. Oct 1, 20254 EDGAR
  16. Oct 1, 2025SCHEDULE 13D/A EDGAR
  17. Sep 5, 2025424B5 EDGAR
  18. Aug 12, 2025SCHEDULE 13G/A EDGAR
  19. Aug 8, 202510-Q EDGAR
  20. Jul 9, 20258-K EDGAR

The 202 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

10 open-market trades by officers, directors and large owners since October 2021: 6 buys and 4 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 30, 2025Herskowitz NeilDirectorSale247$0.96$237Form 4
Dec 30, 2025Chill Adam J.DirectorSale4$0.95$4Form 4
Dec 30, 2025Jin DavidDirectorBuy247$0.96$237Form 4
Sep 13, 2022Litchman Manuel MDPresident, CEO and Interim CFOBuy5,000$0.52$2.6KForm 4
Sep 13, 2022ROSENWALD LINDSAY A MDDirectorBuy5,000$0.52$2.6KForm 4
Mar 18, 2022Litchman Manuel MDPresident, CEO and Interim CFOBuy5,000$0.74$3.7KForm 4
Mar 18, 2022ROSENWALD LINDSAY A MDDirectorBuy4,094$0.74$3.0KForm 4
Dec 14, 2021Achenbach BrianSVP, Fin. & Corp. ControllerSale4,374$1.83$8.0KForm 4
Oct 27, 2021Litchman Manuel MDPresident, CEO and Interim CFOBuy65,000$2.24$145.6KForm 4
Oct 12, 2021Achenbach BrianSVP, Fin. & Corp. ControllerSale4,450$2.28$10.1KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Manuel LitchmanM.D.71$485.5K$498.0K52
2024James Murphy$199.5K$199.5K52
2023PresidentChief Executive Officer and Interim Chief Financial Officer$481.1K$514.5K52

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jun 19, 2024Raised $2.5 million in a private offering of securities Form D: 1 investor so far Form D
  2. Oct 26, 2023Raised $4.7 million in a private offering of equity Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Kestra Advisory Services, LLC196,991$138.3K0.0%+20,949
BlackRock, Inc.84,745$59.5K0.0%No change
Citadel Advisors LLC59,459$41.7K0.0%+6,259
Geode Capital Management, LLC42,240$29.7K0.0%−50,550
CFO4Life Group, LLC33,510$23.5K0.0%+13,049
Vanguard Fiduciary Trust Co32,120$22.5K0.0%No change
Vanguard Capital Management LLC25,704$18.0K0.0%No change
XTX Topco Ltd14,648$10.3K0.0%New
Two Sigma Securities, LLC13,742$9.6K0.0%New
Susquehanna International Group, Llp13,664$9.6K0.0%New
UBS Group AG4,155$2.9K0.0%+496
Tower Research Capital LLC (TRC)1,895$1.3K0.0%No change
Barclays PLC1,121$7870.0%New
SBI Securities Co., Ltd.509$3570.0%No change
Morgan Stanley118$830.0%No change
Virtu Financial LLC14,356$100.0%New
Cullen/Frost Bankers, Inc.13$90.0%No change
Bnp Paribas Financial Markets6$40.0%No change
Lanark Financial, Inc.3$20.0%No change
Jpmorgan Chase & Co2$10.0%No change
Danske Bank A/s2$10.0%No change
Group One Trading LLC1$10.0%No change
Osaic Holdings, Inc.2$10.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How MUSTANG BIO, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMUSTANG BIO, INC.1
  • CIK0001680048
  • Employer ID (EIN)47-38287605
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address95 Sawyer Rd, Suite 110, Waltham, MA 024531
  • Phone78165245001
  • Shares outstanding845,385 Common Class A shares; 6,732,092 Common Unspecified Class shares as of Mar 17, 20265
  • Public float$3.2M as of Jun 30, 20255
  • AuditorKPMG LLP, New York, NY PCAOB ID 185; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceJul 28, 20161
  • Filings403 in all: 8-K (112), 4 (64), 10-Q (30), UPLOAD (18), CORRESP (17), 424B5 (15), 3 (14), EFFECT (11)1
    All 42 form types

    10-K (10), DEF 14A (9), DEFA14A (7), DEF 14C (6), PRE 14C (6), S-3 (6), S-8 (6), 424B3 (5), D/A (5), S-1/A (5), SC 13G (5), 3/A (4), D (4), S-1 (4), SCHEDULE 13D/A (4), 10-12G/A (3), 4/A (3), CT ORDER (3), PRE 14A (3), SC 13D/A (3), SCHEDULE 13G/A (3), 424B4 (2), PX14A6G (2), S-3/A (2), SC 13G/A (2), SCHEDULE 13G (2), 10-12G (1), 10-Q/A (1), 8-A12B (1), CERTNAS (1), POS AM (1), POS EX (1), PRER14C (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Mar 19, 2026
    Quarterly report (10-Q) Aug 5, 2026
    Proxy statement (DEF 14A) Dec 3, 2025
    Latest 8-K (8-K) Oct 15, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareMBIONasdaq

From the cover page of the 10-K filed Mar 19, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks MUSTANG BIO, INC. names in Item 1A of its 10-K filed Mar 19, 2026: 67 risks under these headings, as written.5

  • Risks Related to Our Finances and Capital Requirements
  • We have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. We do not have any products that are approved for commercial sale and therefore do not expect to generate any revenues from product sales in the foreseeable future, if ever.
  • We may in the future need to raise substantial additional funding, which may not be available on acceptable terms to us, or at all. If we are unable to raise capital, we could be required to delay, limit or terminate our product development efforts or other operations, or seek bankruptcy protection or other alternatives that would likely result in our securityholders losing some or all of their investment in us.
  • Our limited operating history makes it difficult to evaluate our business and prospects.
  • SEC regulations limit the amount of funds we can raise during any 12-month period pursuant to our shelf registration statement on Form S-3.
  • Raising additional capital, including through lending arrangements, may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights.
  • We will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.
  • We are a "smaller reporting company," and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.
  • Our ability to use our pre-change net operating loss carryforwards and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation.
  • Risks Related to Our Business Strategy, Structure, and Organization
  • We currently have no products for sale. We are heavily dependent on the success of our product candidates, and we cannot give any assurances that any of our product candidates will receive regulatory approval or be successfully commercialized.
  • Our approach to the development of our product candidates is unproven, and we do not know whether we will be able to develop any products of commercial value.
The other 57 risks
  • CAR T is a relatively new approach to cancer treatment that presents significant challenges.
  • We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • Risks Inherent in Drug Development and Commercialization
  • Delays in the commencement or conduct of our clinical trials could result in increased costs and delay our ability to pursue regulatory approval.
  • Suspensions or delays in the completion of clinical testing could result in increased costs, and delay or prevent our ability to complete development of that product candidate or generate product revenues, if approved.
  • Product candidates that we advance into clinical trials may not receive regulatory approval.
  • Any product candidates we advance into clinical development are subject to extensive regulation, which can be costly and time consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize product candidates.
  • Regulatory approval for our product candidates by the FDA, or any similar regulatory authorities outside the United States, is limited to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.
  • If any of our product candidates are approved and we, or our contract manufacturer(s), fail to produce the product, or components of the product, in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the commercialization of our product candidates, if approved, or be unable to meet market demand, and may lose potential revenues.
  • If serious adverse events are identified during the development of one or more of our product candidates or any future product candidate, we may need to abandon or limit the development of some of our product candidates.
  • Even if one or more of our product candidates receives regulatory approval, it and any other products we may market will remain subject to substantial regulatory scrutiny.
  • We will need to obtain FDA approval of any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business.
  • Public concern regarding the safety of drug products could delay or limit our ability to obtain regulatory approval, result in the inclusion of unfavorable information in our labeling, or require us to undertake other activities that may entail additional costs.
  • If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
  • If our competitors develop treatments for any of our product candidates’ target indications and those competitor products are approved more quickly, marketed more successfully or demonstrated to be more effective, the commercial opportunity for our product candidate will be reduced or eliminated.
  • If any of our product candidates are successfully developed but, if approved, do not achieve broad market acceptance among physicians, patients, healthcare payors and the medical community, the revenues that any such product candidates generate from sales will be limited.
  • Reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our products profitably.
  • If we are unable to establish sales, marketing and distribution capabilities or to enter into agreements with third parties to market and sell our product candidates, we may be unsuccessful in commercializing our product candidates, if they are approved.
  • We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for one or more of our product candidates or a future product candidate, if approved, we may license or acquire and may have to limit their commercialization.
  • Product candidates, even if successfully developed and commercialized, may be effective only in combating certain specific types of cancer, and the market for drugs designed to combat such cancer type(s) may be small and unprofitable.
  • Negative public opinion and increased regulatory scrutiny of the therapies that underpin many of our product candidates may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.
  • Changes in U.S. government policy, regulation, enforcement priorities, and funding decisions could adversely affect our business, financial condition and results of operations.
  • Risks Related to Reliance on Third Parties
  • We rely, and expect to continue to rely, on third parties to conduct our preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or complying with applicable regulatory requirements.
  • We are currently reliant on COH, Nationwide and UAB for all of our research and development efforts and the early clinical testing of our product candidates.
  • We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and may also do so for commercialization, if and when our product candidates are approved. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or any future product candidate or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
  • We rely on third parties to conduct all aspects of our LV vector production and these third parties may not perform satisfactorily.
  • We rely on clinical data and results obtained by third parties that could ultimately prove to be inaccurate or unreliable.
  • We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
  • Collaborative relationships with third parties could cause us to expend significant resources and incur substantial business risk with no assurance of financial return.
  • The contractual provisions we may be forced to agree upon in services, manufacturing, supply and other agreements may be inordinately one-sided, vis-à-vis current or historical standard market terms (especially as it pertains to contractual liability and indemnification paradigms), and as a result we may be subject to liabilities that are not attributable to our own actions or the actions of our personnel.
  • Risks Relating to Legislation and Regulation Affecting the Biopharmaceutical and Other Industries
  • We are subject to new legislation, regulatory proposals and managed care initiatives that may increase our costs of compliance and adversely affect our ability to market our products, obtain collaborators and raise capital.
  • Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business or the business of our partners.
  • Our current and future relationships with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.
  • Risks Related to Intellectual Property and Potential Disputes Thereof
  • If we are unable to obtain and maintain sufficient patent protection for our technology and products, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.
  • We depend on our licensors to maintain and enforce the intellectual property covering certain of our product candidates. We have limited, if any, control over the resources that our licensors can or will devote to securing, maintaining, and enforcing patents protecting our product candidates.
  • Protecting our proprietary rights is difficult and costly, and we may be unable to ensure their protection.
  • We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful, and an unfavorable outcome in any litigation would harm our business.
  • If we or our licensors are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.
  • Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
  • If we fail to comply with our obligations under our intellectual property licenses and third-party funding arrangements, we could lose rights that are important to our business.
  • We may be subject to claims that our employees and/or consultants have wrongfully used or disclosed to us alleged trade secrets of their former employers or other clients.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • We in-license intellectual property pertaining to certain product candidates from third parties. As such, any dispute with the licensors or the non-performance of such license agreements may adversely affect our ability to develop and commercialize the applicable product candidates.
  • Risks Relating to Our Control by Fortress
  • Fortress controls a voting majority of our common stock.
  • Fortress has the right to receive a significant grant of shares of our common stock annually which will result in the dilution of your holdings of common stock upon each grant, which could reduce their value.
  • We might have received better terms from unaffiliated third parties than the terms we receive in our agreements with Fortress.
  • The dual roles of our directors who also serve in similar roles with Fortress could create a conflict of interest and will require careful monitoring by our independent directors.
  • General Risks and Risks Associated with Ownership of our Common Stock
  • We rely on information technology, and our business, reputation and operations would suffer in the event of any internet or internal computer system failures, inadequacies, interruptions, compromises, deficiencies, cyber-attacks, or other cybersecurity incidents affecting our systems or those of our third-party providers, or by any compromise of confidential information.
  • Our growth is subject to economic and geopolitical conditions.
  • We may not be able to manage our business effectively if we are unable to attract and retain key personnel.
  • Our employees, consultants, or third-party partners may engage in misconduct or other improper activities, including but not necessarily limited to noncompliance with regulatory standards and requirements or internal procedures, policies or agreements to which such employees, consultants and partners are subject, any of which could have a material adverse effect on our business.
  • The occurrence of a catastrophic disaster could damage our facilities beyond insurance limits, or we could lose key data which could cause us to curtail or cease operations.
  • The market price for our common stock has been volatile and may continue to fluctuate or may decline significantly in the future.
  • We may become involved in securities class action litigation that could divert management’s attention and harm our business.
  • If we are unable to maintain compliance with all applicable continued listing requirements and standards of Nasdaq, our common stock may be delisted from Nasdaq.

Legal proceedings

We are not involved in any legal proceedings that we believe could have a material adverse effect on our financial position or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of our executive officers, threatened against or affecting our company or our officers or directors in their capacities as such.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52